Spruce Biosciences appoints Keli Walbert to Board of Directors

SPRUCE BIOSCIENCES, INC.

Keli Walbert appointed as Class I Director effective December 11, 2025, term expiring at 2027 annual meeting.
Granted nonstatutory stock option to purchase 3,400 shares vesting monthly over three years.
Annual cash retainer: $40,000 as director; $5,000 for Compensation Committee (increasing to $5,500 in 2026).
Eligible for annual option grant of 1,700 shares starting with 2026 annual meeting, vesting over one year.
Entered into standard indemnification agreement; no related-party transactions disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.